论文部分内容阅读
1例73岁男性骨髓增生异常综合征患者因长期输血出现铁负荷过载，给予地拉罗司分散片（地拉罗司）500 mg口服、1次/d。肾功能检查未见明显异常。10个月后，因铁负荷过载治疗效果不佳，将地拉罗司剂量增至1 000 mg、1次/d。剂量调整约1个月后，患者乏力加重，实验室检查示血尿素氮（BUN）11.5 mmol/L，血清肌酐（Scr）143 μmol/L，估算肾小球滤过率（eGFR）45 ml/(min·1.73 mn 2)。诊断为肾损伤，考虑可能为地拉罗司所致。停用该药，并给予百令胶囊。约1个月后，患者肾功能改善[BUN 9.1 mmol/L，Scr 111 μmol/L，eGFR 60 ml/(min·1.73 mn 2)]。患者因铁负荷过载再次加用地拉罗司1 000 mg口服、1次/d。服药约1个月后，再次出现肾损伤[BUN 9.7 mmol/L，Scr 131 μmol/L，eGFR 49 ml/(min·1.73 mn 2)]，遂将地拉罗司减量为500 mg、1次/d。约3个月后，患者肾功能改善[BUN 8.8 mmol/L，Scr 104 μmol/L，eGFR 65 ml/(min·1.73 mn 2)]。n “,”A 73-year-old male patient with myelodysplastic syndrome received deferasirox dispersible tablets (deferasirox) 500 mg once daily for post-transfusion iron overload. Renal function examination showed no obvious abnormality. Ten months later, the dose of deferasirox was increased to 1 000 mg once daily due to ineffective iron overload treatment. About 1 month after the dose adjustment, the patient′s fatigue was aggravated. Laboratory tests showed blood urea (BUN) 11.5 mmol/L, serum creatinine (Scr) 143 μmol/L, and estimated glomerular filtration rate (eGFR) 45 ml/(min·1.73 m n 2). Kidney injury was diagnosed, which was considered to be induced by deferasirox. Then deferasirox was stopped and n Corbrin capsule (百令胶囊) was given. About 1 month after drug withdrawal, renal function of the patient was improved [BUN 9.1 mmol/L, Scr 111 μmol/L, and eGFR 60 ml/(min·1.73 m n 2)]. Due to the iron overload, deferasirox was re-given at dose of 1 000 mg once daily. About 1 month after medication, the kidney injury recurred [BUN 9.7 mmol/L, Scr 131 μmol/L, and eGFR 49 ml/(min·1.73 m n 2)]. The dose of deferasirox was reduced to 500 mg once daily immediately and 3 month later, renal function of the patient was improved [BUN 8.8 mmol/L, Scr 104 μmol/L, and eGFR 65 ml/(min·1.73 m n 2)].n